期刊中文名:腫瘤醫(yī)學(xué)病例報(bào)告ISSN:2090-6706E-ISSN:2090-6714
該雜志國(guó)際簡(jiǎn)稱(chēng):CASE REP ONCOL MED,是由出版商Hindawi Limited出版的一本致力于發(fā)布--研究新成果的的專(zhuān)業(yè)學(xué)術(shù)期刊。主要發(fā)表刊登有創(chuàng)見(jiàn)的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專(zhuān)論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。
《Case Reports In Oncological Medicine》是一本以English為主的開(kāi)放獲取國(guó)際優(yōu)秀期刊,中文名稱(chēng)腫瘤醫(yī)學(xué)病例報(bào)告,本刊主要出版、報(bào)道領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專(zhuān)業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專(zhuān)業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為0.6,
Case Reports in Oncology Medicine is a peer-reviewed open access journal focused on the field of oncology. This magazine publishes case reports related to various cancers, aiming to provide a platform for clinical doctors, researchers, and healthcare professionals to share unique cases, rare disease manifestations, treatment challenges, and innovative therapies. These case reports help to enhance understanding of cancer biology, diagnosis, treatment, and management, while also guiding future clinical practice and research directions.
The journal emphasizes the educational significance and scientific contribution of cases, encourages submission of detailed case descriptions, comprehensive literature reviews, and in-depth discussions. In this way, the magazine not only promotes the dissemination of individual case knowledge, but also helps to build a broader oncology community, thereby improving the quality of patient care worldwide. The types of contributions accepted by the magazine include single case reports and case series, and research topics cover a wide range of fields such as breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology, and urogenital cancer. These studies are of great significance for promoting clinical progress and personalized medicine in oncology.
按JIF指標(biāo)學(xué)科分區(qū) |
學(xué)科:ONCOLOGY
收錄子集:ESCI
分區(qū):Q4
排名:299 / 322
百分位:
7.3% |
按JCI指標(biāo)學(xué)科分區(qū) |
學(xué)科:ONCOLOGY
收錄子集:ESCI
分區(qū):Q4
排名:298 / 322
百分位:
7.61% |
JCR分區(qū):JCR分區(qū)來(lái)自科睿唯安公司,JCR是一個(gè)獨(dú)特的多學(xué)科期刊評(píng)價(jià)工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計(jì)信息的期刊評(píng)價(jià)資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個(gè)具體學(xué)科。JCR分區(qū)根據(jù)每個(gè)學(xué)科分類(lèi)按照期刊當(dāng)年的影響因子高低將期刊平均分為4個(gè)區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個(gè)部分的。
該雜志是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有較高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,該雜志在綜合專(zhuān)業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對(duì)稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求很高,作為一本國(guó)際優(yōu)秀雜志,一般投稿過(guò)審時(shí)間都較長(zhǎng),投稿過(guò)審時(shí)間平均 16 Weeks ,如果想投稿該刊要做好時(shí)間安排。版面費(fèi)不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請(qǐng)咨詢(xún)客服。
若用戶(hù)需要出版服務(wù),請(qǐng)聯(lián)系出版商。